...
首页> 外文期刊>Contemporary Clinical Trials Communications >Evaluation of efficacy and safety of a novel lipogel containing diclofenac: A randomized, placebo controlled, double-blind clinical trial in patients with signs and symptoms of osteoarthritis
【24h】

Evaluation of efficacy and safety of a novel lipogel containing diclofenac: A randomized, placebo controlled, double-blind clinical trial in patients with signs and symptoms of osteoarthritis

机译:含有双氯芬酸的新型Lipogel的功效和安全性评价:患有骨关节炎患者的随机,安慰剂控制,双盲临床试验

获取原文

摘要

BackgroundEffectiveness and safety of pharmaceuticals is the prime concern of every osteoarthritis (OA) treatment. Chronic administration of NSAIDs, especially in case of geriatrics, through oral route tend to compromise the patient's safety, whereas topical treatments are not found to be effective owing their poor ability to deliver drug molecules.Thus, the present study deals with a randomized, double-blind, controlled trial conducted on patients with knee osteoarthritis (OA) for comparing the performance of a novel topical gel (liposomal gel) of diclofenac with a placebo and a marketed gel.MethodsThe patients were treated and evaluated for 6 weeks as per the Western Ontario McMaster Universities (WOMAC) Index for OA. Patients were also observed for any adverse events. All the results were analyzed statistically using Kruskal-Wallis test, followed by Student's t-test at p?≤?0.05.ResultsPatients treated with liposomal gel showed statistically significantly improvements in treatment in comparison to the other tested formulations. All the treatments were found to be well tolerated with no report of adverse event. The results unequivocally demonstrated the superiority of the diclofenac liposomal gel, in the relieving the symptoms of OA of the knee, in comparison to placebo and marketed gel.ConclusionFrom above results it was revealed that the drug in liposome have higher therapeutic potential. Thus, this can be a safe and effective option for the management of chronic OA especially for geriatric patients.
机译:制备药物的背景和安全性是每种骨关节炎(OA)治疗的主要关注点。慢性施用NSAIDs,特别是在老年人的情况下,通过口腔路线倾向于损害患者的安全性,而局部治疗尚未发现其递送药物分子的能力差,而目前的研究涉及随机,双重-Blind,对膝关节骨关节炎(OA)患者进行的对照试验,用于比较Diclofenac的新型局部凝胶(脂质体凝胶)与安慰剂和销售的凝胶的性能。根据西方的西方治疗和评估患者6周的患者Ontario McMaster大学(Womac)OA指数。对于任何不良事件,也观察到患者。所有结果都使用Kruskal-Wallis试验进行统计分析,然后在P?≤0.05.用脂质体凝胶处理的培养物分析,与其他测试的制剂相比,治疗治疗的核心显着改善。发现所有治疗都没有耐受性耐受性良好的事件。结果明确地证明了双氯芬酸脂质体凝胶的优越性,在缓解膝盖的OA症状中,与安慰剂和销售凝胶相比。结论从上面的结果,揭示了脂质体中的药物具有更高的治疗潜力。因此,这可能是一种安全有效的选择慢性OA,尤其是对老年患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号